...published online Dec. 12, 2018 doi:10.1038/s41467-018-07698-6 CONTACT: Elisa Ciraolo, University of Turin, Turin, Italy email: Elisa.Ciraolo@mdc-berlin.de Claire...

...doi:10.1016/j.chembiol.2018.10.013 CONTACT: Erich E. Wanker, Max Delbrück Center for Molecular Medicine Berlin-Buch, Berlin, Germany email: ewanker@mdc-berlin.de Claire...

...by blocking the chemokine receptor’s interaction with its ligands chemokine CC motif ligand 22 (CCL22; MDC...

...2017 doi:10.1038/s41467-017-01220-0 CONTACT: Young-Ae Lee, Max Delbrück Center for Molecular Medicine Berlin-Buch, Berlin, Germany email: yolee@mdc-berlin.de Elizabeth...

...to selectively inhibit Tregs.” FLX Bio’s compound blocks the chemokine receptor’s interaction with its ligands CCL22...
...in combination with checkpoint inhibitors to treat solid tumors, and is investigating biomarker candidates, including CCL22...
...Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Targets CCL17 - Chemokine CC motif ligand 17 CCL22 (MDC...

...compound decreased levels of the inflammatory marker chemokine CC motif ligand 22 ( CCL22 ; MDC...

...19, 2017 doi:10.1038/nn.4590 CONTACT: Matthew Poy, Max Delbrück Center for Molecular Medicine, Berlin, Germany email: matthew.poy@mdc-berlin.de Winnie...

...Molecular Medicine, Berlin, Germany email: k.poole@unsw.edu.au CONTACT: Gary R. Lewin, same affiliation as above email: glewin@mdc-berlin.de Hongjiang...

...chemokine CCL22 could help treat metastatic melanoma. In samples of patient skin metastases, levels of CCL22...
...in healthy volunteer skin samples, and in patient blood samples, numbers of Tregs expressing the CCL22...
...xenograft mouse models of metastatic melanoma. TARGET/MARKER/PATHWAY: Chemokine CC motif ligand 22 ( CCL22 , MDC...

...The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to...
...start in 2018 to treat multiple myeloma (MM). Wilex declined to disclose financial terms, and MDC...